Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 431 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lutrepulse Clear all
Active, not recruiting Phase 1 Interventional

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

NCT06531499
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
AAA617, Gonadotropin-releasing hormone (GnRH) analogues, Gonadotropin-releasing hormone (GnRH) antagonists
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 8:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer

NCT01163084
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7
Interventions
Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 24, 2026, 8:59 PM EDT
Terminated Phase 3 Interventional Results available

GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

NCT01257802
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Systemic Vasculitis, Isolated Angiitis of Central Nervous System, Lung Disease With Systemic Sclerosis, Lung Disease Interstitial Diffuse
Interventions
depot leuprolide acetate 3.75 mg, Placebo
Drug
Lead sponsor
Joseph Mccune
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Reproductive Hormones on Mood and Behavior

NCT00001322
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Leuprolide Acetate 3.75, Estradiol, Progesterone, Placebo suppository, Placebo patch
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

NCT02430480
View directory record Official record
Conditions
Prostate Cancer
Interventions
Goserelin, Enzalutamide, mpMRI
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 24, 2026, 8:59 PM EDT
Not listed Phase 3 Interventional Results available

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

NCT00567580
View directory record Official record
Conditions
Prostate Cancer
Interventions
PBRT, PLNRT, AA, LHRH agonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
444
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 316 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer

NCT00225420
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, leuprolide acetate, radiation therapy
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 24, 2026, 8:59 PM EDT
Active, not recruiting Early Phase 1 Interventional

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

NCT03511196
View directory record Official record
Conditions
Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer, Adenocarcinoma of the Prostate
Interventions
Adaptive Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 24, 2026, 8:59 PM EDT
Terminated Phase 3 Interventional Results available

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

NCT03777982
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prednisone, Apalutamide, Abiraterone Acetate, LHRH Agonist or Antagonist
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Boston, Massachusetts • Milford, Massachusetts • South Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 8:59 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

NCT07027124
View directory record Official record
Conditions
Prostate Cancer, High-risk Prostate Cancer
Interventions
Darolutamide, Pembrolizumab, Lupron
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 24, 2026, 8:59 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

NCT04484818
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Darolutamide, Goserelin Acetate, Leuprolide Acetate, Placebo Administration, Quality-of-Life Assessment, Triptorelin
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
115
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 88 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females

NCT00796289
View directory record Official record
Conditions
Infertility
Interventions
GnRH iontophoretic transdermal Lutrepatch, clomiphene citrate, placebo clomiphene citrate, placebo GnRH patch
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 38 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Tucson, Arizona • Jonesboro, Arkansas • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

NCT00833248
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Goserelin, Bicalutamide
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
19
States / cities
Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 24, 2026, 8:59 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading

NCT01763541
View directory record Official record
Conditions
Hypertension
Interventions
leuprolide acetate, Anastrozole
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 24, 2026, 8:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of PF-06873600 in People With Cancer

NCT03519178
View directory record Official record
Conditions
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Interventions
PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 24, 2026, 8:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Endometrial Receptivity Profile in Patients With Endometrial Proliferation Defects

NCT02406690
View directory record Official record
Conditions
Endometrial Dysfunction
Interventions
Estradiol Valerate, Progesterone in Oil, Leuprolide
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature

NCT00001190
View directory record Official record
Conditions
Dwarfism, Growth Disorder
Interventions
Deslorelin
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1983 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 8:59 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

NCT04671966
View directory record Official record
Conditions
Heart Diseases, Left Ventricular Dysfunction
Interventions
Estradiol patch, Cetrotide, Fasting, Lower Body Negative Pressure
Drug · Other
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 30 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reproductive Hormonal Alterations in Obesity

NCT01457703
View directory record Official record
Conditions
Obesity
Interventions
Cetrorelix, Gonadorelin-GnRH, Recombinant LH, Letrozole
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

NCT00003394
View directory record Official record
Conditions
Prostate Cancer
Interventions
carboplatin, endocrine-modulating drug therapy, estramustine phosphate sodium, goserelin acetate, leuprolide acetate, paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 1 Interventional

Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate

NCT02064036
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Stereotactic Radiosurgical Boost, Casodex, Leuprolide
Radiation · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

NCT00924469
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone, Leuprolide, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Boston, Massachusetts • Houston, Texas • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 24, 2026, 8:59 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT01368588
View directory record Official record
Conditions
Prostate Cancer
Interventions
three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
2,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
454
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

AASUR in High Risk Prostate Cancer

NCT02772588
View directory record Official record
Conditions
Prostate Cancer
Interventions
ARN-509, Abiraterone, Leuprolide, stereotactic, ultra-fractionated radiotherapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
11
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 24, 2026, 8:59 PM EDT